Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

EUCRATES BIOMEDICAL ACQUISITION CORP.

(EUCR)
 SummaryQuotesChartsNewsCompanyFinancials 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
01/07/2022 01/10/2022 01/11/2022 01/13/2022 01/14/2022 Date
0(c) 0(c) 9.82(c) 0(c) 9.8(c) Last
10 21 1 866 5 9 900 Volume
-100.00% -100.00% Change
More quotes
Estimated financial data (e) (USD)
Sales 2019
Net income 2019
Net Debt 2019
P/E ratio 2019
Yield 2019
Sales 2020 - - -
Net income 2020 -14,8 M - -
Net cash position 2020 0,55 M - -
P/E ratio 2020 -
Yield 2020 -
Capitalization 132 M 132 M -
EV / Sales 2019
EV / Sales 2020 -
Nbr of Employees -
Free-Float -
More Financials
Company
Eucrates Biomedical Acquisition Corp. is a blank check company. The Company is formed for the purpose of acquiring, engaging in a share exchange, share reconstruction and amalgamation with, purchasing all or substantially all of the assets of, entering into contractual arrangements with, or engaging in any other similar business combination with one or more businesses or entities. The Company intends to focus on... 
Sector
Investment Holding Companies
Calendar
-
More about the company
All news about EUCRATES BIOMEDICAL ACQUISITION CORP.
2021EUCRATES BIOMEDICAL ACQUISITION CORP. - 10-K/A - Management's Discussion and Analysis o..
AQ
2021EUCRATES BIOMEDICAL ACQUISITION CORP. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIA..
AQ
2021Eucrates Biomedical Acquisition Corp. Reports Earnings Results for the Third Quarter an..
CI
2021EUCRATES BIOMEDICAL ACQUISITION CORP : Non-Reliance on Previous Financials, Audits or Inte..
AQ
2021EUCRATES BIOMEDICAL ACQUISITION : MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDIT..
AQ
2021EUCRATES BIOMEDICAL ACQUISITION : MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDIT..
AQ
2021Eucrates Biomedical Acquisition Corp. Reports Earnings Results for the First Quarter En..
CI
2021EUCRATES BIOMEDICAL ACQUISITION : 10-K/A - Management's Discussion and Analysis of Financi..
AQ
2021EUCRATES BIOMEDICAL ACQUISITION CORP : Non-Reliance on Previous Financials, Audits or Inte..
AQ
2021EUCRATES BIOMEDICAL ACQUISITION : Receives Non-Compliance Notice from Nasdaq
MT
2021EUCRATES BIOMEDICAL ACQUISITION : RECEIVES EXPECTED NOTICE FROM NASDAQ REGARDING DELAYED Q..
PU
2021EUCRATES BIOMEDICAL ACQUISITION CORP : Notice of Delisting or Failure to Satisfy a Continu..
AQ
2021Certain Ordinary Shares of Eucrates Biomedical Acquisition Corp. are subject to a Lock-..
CI
2021EUCRATES BIOMEDICAL ACQUISITION : Management's Discussion and Analysis of Financial Condit..
AQ
2021Eucrates Biomedical Acquisition Corp. Announces Earnings Results for the Period from Au..
CI
More news
News in other languages on EUCRATES BIOMEDICAL ACQUISITION CORP.
2021L'acquisition d'Eucrates Biomedical reçoit un avis de non-conformité du Nasdaq
More news
Chart EUCRATES BIOMEDICAL ACQUISITION CORP.
Duration : Period :
Eucrates Biomedical Acquisition Corp. Technical Analysis Chart | EUCR | VGG3141W1068 | MarketScreener
Income Statement Evolution
Managers and Directors
Parag Phoolchand Saxena Chief Executive Officer & Director
Evangelos Vergetis President, Chief Operating Officer & Director
Gonzalo Cordova Chief Financial Officer
Stelios Papadopoulos Chairman
Daphne Karydas Independent Director